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Abstract: It is now almost 60 years since the discovery of melatonin and new physiological functions of the indole continuously
appear in the most recent studies worldwide. Experimental evidence emphasizes its importance as a stabilizer of the mitochondrial
bioenergetics, which could be related to the prevention of development of aging and several diseases. In the next years, conscientious
investigation about this topic should be undertaken by scientists of different research areas to achieve a better understanding of the
molecular mechanisms implied. This will ultimately allow the development and clinical application of efficacious treatments.
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1. Introduction
It is now almost 60 years since the discovery of melatonin
and new physiological functions of the indole continuously
appear in the most recent studies worldwide. Besides the
pineal gland, the existence and value of other sources of
synthesis force us to rethink the established premises about
the biological role of this molecule, such as the well-known
regulation of circadian and reproductive cycles (Hardeland
et al., 2008). In the last few years, other properties of
melatonin such as antioxidant power, immunoregulatory
capacity, and oncostatic action have enriched our
knowledge about the pleiotropic nature of the hormone.
The role of melatonin in mitochondrial homeostasis has
gained strength in the scientific community. Experimental
evidence emphasizes its importance as a stabilizer of
organular bioenergetics, which could be related to the
prevention of development of aging and several diseases.
2. Melatonin and mitochondria: origin and status of a
relationship
Recently, Tan et al. (2014) proposed that ability to
synthesize melatonin in eukaryotes could be inherited
from prokaryotic cells, particularly from photosynthetic
alpha-proteobacteria. As the authors noted, the alphaproteobacteria are a group of bacteria currently accepted
as being the precursors of mitochondria and probably
the oldest organisms with the capacity to synthesize
melatonin. Hence, following the endosymbiotic theory,
mitochondria may be the original site of melatonin
* Correspondence: ccarom@unex.es
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production in eukaryotic cells and may still possess this
capacity at present. Interestingly, it has been recorded that
the indolamine is concentrated particularly in subcellular
compartments (to levels of 100 nM) such as the nucleus and
mitochondria, the latter showing higher concentrations
than cytosol and serum (Escames et al., 2010; Phillipson,
2014).
Besides being sites of important metabolic reactions
(steroid hormone/porphyrin synthesis, urea cycle, lipid
metabolism, amino acid interconversion, xenobiotic
metabolism, glucose sensing/insulin regulation, and
cellular Ca2+ homeostasis), mitochondria are the major
generators of cellular energy (Brookes et al., 2004). This
last feature converts them also into the major sources of
potentially harmful reactive species. However, some of
these radicals are key elements for basic cell signaling
processes. For this reason, steady-state maintenance of free
radical/antioxidant ratio appears to be the key for optimal
mitochondrial functioning (Sheu et al., 2006; Morley et al.,
2012).
This is where the close relationship between
mitochondria and melatonin lies. Once indole reaches
the organelle, its lipophilicity allows it to accumulate
in the inner mitochondrial membrane, close to the
electron transport chain (ETC) (Petrosillo et al., 2006).
The mitochondrial ETC is a system of oxidoreductant
protein complexes (C-I, -II, -III, and -IV), responsible
for approximately 90%–95% of cell ATP production
through the metabolic process known as oxidative
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phosphorylation (OXPHOS) in aerobic cells (Reiter et
al., 2003). It is thought that melatonin counteracts the
leakage of electrons derived from deficiencies in the ETC
function in several ways; for example, it has been seen that
melatonin administration increases C-I and C-IV activities
in a dose-dependent manner (Martin et al., 2000a, 2000b)
and even enhances gene expression of C-IV components
(Hardeland et al., 2005). Single-electron exchange may
be the basis for these beneficial interactions, an effect
not shared by other antioxidants (Paradies et al., 2010;
Srinivasan et al., 2010). On balance, melatonin would
make mitochondrial respiration and ATP synthesis more
efficient. Thus, quasicatalytic amounts of melatonin would
be required for radical formation avoidance; additionally,
one of its metabolites, N1-acetyl-5-methoxykynuramine
(AMK), could also be implicated in this kind of singleelectron transfer reaction (Hardeland et al., 2005).
This feature leads us to the next mechanism of action
of melatonin on mitochondrial homeostasis. As it has been
mentioned, mitochondria are major sites of free radical
production and it is largely recognized that melatonin acts
as a scavenger of free radicals already formed. Thereby,
high concentrations of melatonin within mitochondria
would be advantageous to avoid oxidative damage, due
to the antioxidant properties of the molecule (Reiter
et al., 2008). In this way, related to inner mitochondrial
membrane essential components, not only are the above
mentioned protein complexes of ETC protected from
the harmful effects caused by reactive oxygen/nitrogen
species (ROS/RNS), but also phospholipidic elements
are safeguarded from lipid peroxidation (Stetinová et al.,
2002). Among them, cardiolipin (CL) is biosynthesized
and almost exclusively located in the inner mitochondrial
membrane, where it seems to be involved in the regulation
of several bioenergetic and dynamic processes of the
organelle. Nevertheless, its high content of unsaturated
fatty acids and its location near the site of production of
radicals (C-I and C-III) make it particularly susceptible to
peroxidative attack by ROS. This phenomenon negatively
impacts the structural properties (membrane fluidity and
permeability) and function (respiration and oxidative
phosphorylation) of the mitochondrial membrane, leading
to cellular dysfunction and even cell death (Paradies et al.,
2010). Some studies show that melatonin, at micromolar
concentrations, would prevent the oxidation/depletion of
CL (Petrosillo et al., 2006, 2008).
On the other hand, there are some other aspects that
cannot be forgotten in relation to melatonin’s effects on
mitochondria. Scientific evidence reflects that melatonin
and its metabolite AMK could be able to inhibit
production of nitric oxide (NO) and consequently the
formation of peroxynitrite radical (ONOO-), regulating
the activity of mitochondrial nitric oxide synthase.

Besides being a signalization molecule, NO has been
demonstrated to be a potent reversible inhibitor of cell
respiration (at the C-IV level), inducing impairment of
ATP synthesis and, eventually, apoptosis and cell death
(Freitas et al., 2006; Luchetti et al., 2010). Nevertheless,
nowadays is not clear if this effect could differ according
to melatonin concentration, affected tissues, or metabolic
requirements. In fact, recently Sarti et al. (2013) observed
that mRNA expression of neuronal nitric oxide synthase
(nNOS) in HaCat cells (a spontaneously transformed
human keratinocyte cell line, widely used for its
high capacity to differentiate and proliferate in vitro)
(Boukamp et al., 1988; Schoop et al., 1999) is increased
at nanomolar concentrations of the indole. Conversely,
at higher intracellular concentrations of melatonin (and/
or its metabolites), a progressive enzymatic inhibition
is recorded; simultaneously, the consequent lowered
ATPOXPHOS production is balanced by glycolysis. As the
authors pointed out, mechanisms involved in this biphasic
behavior remain unclear, but they could be related to
competition between melatonin and nNOS for binding
with calmodulin.
Melatonin also exerts indirect antioxidant actions
through promotion of antioxidant enzymatic activity in
mitochondria, which ultimately has positive repercussions
on ETC function. Glutathione (GSH) and its related
enzymes glutathione peroxidase (GPx) and reductase
(GRd) are the main mitochondrial antioxidant system;
a lack in catalase activity makes mitochondria almost
entirely dependent on cytosolic GSH and its recycling
enzymes (Martin et al., 2000a; Reiter et al., 2003). Some
studies have shown that melatonin regulates GSH redox
status in brain and liver mitochondria (Martin et al.,
2000a). Furthermore, it seems that melatonin may
promote de novo synthesis of GSH by stimulating the
activity of the enzyme γ-glutamyl-cysteine synthetase
(Srinivasan et al., 2011). In relation to this, melatonin
has the ability to preserve the nicotinamide nucleotides
NADPH and NADH, essential for the activity of GRd.
Thus, this could be another mechanism implied in the
maintenance of GSH levels, which would prevent in turn
both inhibition of C-I by NO and extensive mitochondrial
damage produced by hydrogen peroxide (H2O2) (Martin
et al., 2000a; Phillipson, 2014). Moreover, NAD recycling
to NADH by melatonin facilitates ATPOXPHOS production,
since NADH acts as a substrate for C-I (Tan et al., 2005;
Phillipson, 2014). In summary, as can be noted, the
indolamine at mitochondrial level acts as a multifactorial
and powerful antioxidant, influencing several components
of a complex network that need to be totally clarified.
It is well established that mitochondria are arbiters of life
and death, playing a decisive role in signaling of apoptosis
and necrosis in the function of oxidative damage grade
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suffered. Consequently, antioxidants able to reduce the
production of ROS/RNS at the mitochondrial level would
be expected to limit cellular death (Reiter et al., 2008). In
normal cells exposed to different experimental conditions,
melatonin has the ability to avoid apoptotic cascade. Some
authors have demonstrated that the indolamine prevents
opening of the mitochondrial permeability transition pore
(mPTP) caused by alterations of Ca2+ homeostasis (del
Castillo-Vaquero et al., 2010; Santofimia-Castaño et al.,
2014) and also restores mitochondrial membrane potential
(Δψm) (Xu et al., 2002; Espino et al., 2011). According
to Espino et al. (2010), melatonin could also exert its
antiapoptotic effects through prevention of Bax activation,
release of cytochrome C, and activation of caspases 3 and
9. For others, protection of CL from lipid peroxidation
could be another suitable molecular mechanism implied,
because this lipid is responsible for the anchorage of
cytochrome C in the inner membrane of mitochondria
(Luchetti et al., 2010). Interestingly, melatonin has shown
a prooxidant effect on tumor cell lines, thus promoting
intracellular ROS generation and apoptosis (Bejarano et
al., 2011a). In this case, the events described above are
induced in the presence of millimolar concentrations of
melatonin, which strongly suggests involvement of the
mitochondrial-mediated (intrinsic) pathway of apoptosis
(Bejarano et al., 2009). Thereby, the indolamine seems to
enhance the viability of normal cells at low pharmacological
concentrations (1 µM to 10 nM), being prooxidant at high
concentrations (1–0.1 mM) in several human tumoral cells
(Bejarano et al., 2011a). It should be noted that antioxidant
and scavenger capacities of melatonin may also intervene
(Espino et al., 2010; Luchetti et al., 2010). This dual action
could be exploited not only to protect healthy cells but also
to increase selective effects of anticancer agents during
chemotherapy (Bejarano et al., 2011b).
Oxidative stress may damage other important
components of mitochondria, leading to lethal cell injury.
Mitochondrial DNA (mtDNA) is especially susceptible to
attack by ROS because of the close proximity to the ETC
and lack of protective histones (Paradies et al., 2010).
Once more, it has been registered that even in cells with
a common deletion of mtDNA, melatonin would be still
capable of reducing oxidative damage and thus preventing
apoptotic cascade (Jou et al., 2007).
Finally, as Luchetti et al. (2010) mentioned,
melatonin metabolism by itself could contribute to
the defense against oxidative stress. Specifically, phase
I detoxification components such as mitochondrial
cytochrome P450 metabolize the O-demethylation and
hydroxylation at position 2 and 6 of the indolamine,
generating several antioxidant metabolites (N1-acetyl-
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N2-formyl-5-methoxykynuramine,
N-acetylserotonin,
and 2-hydroxymelatonin). This evidence might suggest
a functional linkage between the control of melatonin
metabolism and its mitochondrial-protective function.
In the Figure a summary of different levels of action
of melatonin on mitochondrial function of normal cells is
shown.
3. Role of melatonin on mitochondrial dysfunction and
diseases
The idea that mitochondrial dysfunction is implicated in
the etiology of various diseases has been strengthened after
several years of research. Initially, studies of mitochondrial
diseases have focused on mitochondrial respiratory-chain
diseases associated with mutations of mtDNA. However,
more recent evidence shows that oxidative damage is
responsible for the impairment of mitochondrial function,
leading to a self-induced vicious cycle that finally
culminates in necrosis and apoptosis of cells and organ
failure. We are now starting to understand the mechanisms
of a large list of mitochondrial-related diseases (cancer,
diabetes, obesity, cardiovascular and neurodegenerative
diseases, and aging); all of them seem to share the
common features of disturbances of mitochondrial Ca2+,
ATP, or ROS metabolism (Sheu et al., 2006). Therefore,
selective prevention of such phenomena should be an
effective therapy in a wide range of human diseases (Smith
et al., 1999; Sheu et al., 2006). Melatonin, as was described
in the previous section, has many of the characteristics
of a perfect candidate for the treatment of these kinds of
illnesses. Recent insights about this interesting topic are
summarized below and in the Table.
Cardiolipin
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Figure. Summary of melatonin and mitochondrial function in
a normal cell: action levels (ETC = electron transport chain;
GPx/GRd = glutathione peroxidase/glutathione reductase; M =
melatonin; mPTP = mitochondrial permeability transition pore;
mtDNA = mitochondrial DNA; ROS/RNS = reactive oxygen
species/reactive nitrogen species).
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Table. Summary of experimental articles on melatonin and mitochondrial function on
diseases and aging.

Disorders

References

Aging

Rodríguez et al., 2007
Espino et al., 2011
Acuña-Castroviejo et al., 201

Neurodegenerative diseases
Alzheimer disease
Parkinson disease
Huntington disease
Amyotrophic lateral sclerosis
Cancer

Gastrointestinal diseases
Chronic diabetes mellitus
Obesity
Ischemia/reperfusion
Liver
Heart
Brain

Sepsis
Others
Photodamage
Alcoholism

3.1. Aging
Mitochondrial dysfunction plays a major role in the
physiological aging process (Morley et al., 2012). Although
not fully understood, a reduction in mitochondrial
respiration (in terms of efﬁciency of the ETC (C-I and
C-IV), ATP production, underexpression of genes
associated with energy metabolism, etc.) and GPx
activity has been recorded, accompanied by an increase
in oxidation of CL and activation of mPTP, with the
consequent release of proapoptotic factors (Mather and
Rottenberg, 2000; Paradies et al, 2010; Phillipson, 2014).
According to the free radical theory of aging proposed
by Harman (1956), leakage of electrons, overproduction
of ROS/RNS, and possibly accumulation of mtDNA
mutations in postmitotic cells (beginning in adults after

Morley et al., 2012
Dabbeni-Sala et al., 2001
Patki et al., 2011
Wang et al., 2012
Zhang et al., 2013
Bejarano et al., 2009
Bejarano et al., 2011a
Uguz et al., 2012
Wang et al., 2013
Zavodnik et al., 2011
Stacchiotti et al., 2014
Freitas et al., 2006
Petrosillo et al., 2006
Petrosillo et al., 2009
Andrabi et al., 2005
Han et al., 2006
Wang et al., 2009
Lowes et al., 2013
Kleszczyński et al., 2011
Argun et al., 2014
Mansouri et al., 2001

their mid-thirties) are considered to be contributory
factors to age-related degeneration (Rodríguez et al., 2007;
Srinivasan et al., 2011). Additionally, the gradual reduction
in the nocturnal secretion of melatonin throughout
life may contribute to the persistent oxidative damage
and apoptosis signaling, due to failure of antioxidant
protection exerted by the indolamine on the mitochondria
(Reiter et al., 2008; Escames et al., 2010; Phillipson, 2014).
This phenomenon is considered to be the signal for
switching on the mammalian senescence program, which
would decrease the number of cells in organs and tissues
and functional resources until organic senescence of the
organism (Skulachev, 2009; Espino et al., 2012). It has been
demonstrated that huge interindividual variation exists in
circulating levels of melatonin; this phenomenon likely has
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a genetic origin localized in the gene for hydroxyindoleO-methyltransferase, the rate-limiting enzyme in
melatonin synthesis. Thus, different genotypes may cause
different grades of predisposition to age-related diseases
in populations (Srinivasan et al., 2011). Furthermore, as
Acuña-Castroviejo et al. (2012) pointed out, females seem
to be more protected against oxidative stress than males.
The authors hypothesize that this feature could be related,
at least in part, to the regulatory action of sex hormones in
the activities of several complexes of the ETC. Altogether,
this evidence must be taken into account in the future for
melatonin supplementation in the elderly.
In general, the studies conducted in this sense have
shown that chronic treatment with melatonin counteracts
some of the aspects related to the decaying mitochondrial
function in senescence-accelerated mice, such as decreased
ETC and GPx activities (Phillipson, 2014), increased
lipid peroxidation, and reduction of the GSH:GSSG ratio
through promotion of GPx and GRd activity (Rodríguez
et al., 2007; Acuña-Castroviejo et al., 2012), favoring
prosurvival pathways (sirtuins and PI3K/Akt signaling)
versus the intrinsic apoptotic pathway (Espino et al., 2011).
3.2. Neurodegenerative diseases
The mammalian brain is a tissue with high energy demands,
therefore with an active mitochondrial metabolism that
consumes 20% of the total oxygen inspired. Consequently,
ROS generation is intense, as well as the oxidative damage
suffered by mitochondria, a situation worsened by the fact
that the brain contains low concentrations of cytosolic
antioxidants. Oxidative damage to different structural and
functional components of mitochondria such as mtDNA,
proteins (ETC complexes), and membrane lipids has
been reported in a variety of organisms during the aging
process. For instance, cognitive functions, motor ability,
exploratory capacity, and neuromuscular coordination
in mice are decreased upon aging in parallel with these
oxidative phenomena (Escames et al., 2010). In the last few
decades, mitochondrial dysfunction and oxidative stress
have been linked to many neurodegenerative diseases, as
explained below.
Alzheimer disease (AD) is characterized by
extracellular senile plaques of aggregated β-amyloid (Aβ)
and intracellular neuroﬁbrillary tangles that contain
hyperphosphorylated tau protein. Clinical manifestations
include loss of memory and deterioration of cognition.
This feature has led to the classical belief that the pathology
of AD is due to overproduction of Aβ (Srinivasan et
al., 2010). In 2004, Swerdlow and Kahn proposed an
alternative hypothesis for AD called the mitochondrial
cascade hypothesis. This new insight is based on the
premise that damage to mtDNA results in mitochondrial
dysfunction, leading to an increase in oxidative stress
and subsequent activation of Aβ. In addition, it has been
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observed that brains of AD patients have a deﬁciency in
C-IV activity and increased levels of oxidation and/or
nitration of certain proteins. Thus, a diminished synthesis
of ATP results in synaptic dysfunction, apoptosis, and tau
hyperphosphorylation. At present, there is not enough
information to confirm whether Aβ causes mitochondrial
dysfunction and oxidative damage or whether
mitochondrial dysfunction leads to inﬂammation resulting
in excess Aβ production (Escames et al., 2010; Morley et
al., 2012). Other evidence suggests that amyloid precursor
protein (APP) and Aβ are taken up by mitochondria using
the transporter outer membrane. Once there, only a small
fraction is maintained in the mitochondrial matrix and
the rest particularly accumulates in the inner membrane.
The consequent alteration of fatty acid composition and
the derived oxidative stress might influence the membrane
permeabilization, leading to mitochondrial dysfunction
(Rosales-Corral et al., 2012).
Parkinson disease (PD) is an age-related disorder
characterized by a progressive degeneration of
dopaminergic neurons of the substantia nigra pars
compacta and by formation of Lewy bodies (Dabbeni-Sala
et al., 2001; Srinivasan et al., 2010). Oxidative stress, loss
of antioxidant defenses and GSH, and underexpression of
genes associated with energy metabolism are considered as
plausible and interrelated causes of this neurodegenerative
disease. Thus, a deficit in mitochondrial C-I could
contribute to cell degeneration via a direct generation of
ROS, leading to disruption of Ca2+ homeostasis, decrease
in ATP synthesis, and apoptosis (Dabbeni-Sala et al.,
2001; Srinivasan et al., 2010; Patki et al., 2011; Phillipson,
2014). Deficiencies in C-II, C-III, and C-IV have also been
observed in platelets of PD patients (Escames et al., 2010).
Although there is no convincing proof demonstrating a
primary role of inherited mtDNA mutations (Escames et
al., 2010), they must not be discarded as well as implications
of environmental factors in the neurodegenerative disorder
(Patki et al., 2011).
Huntington disease (HD) is an autosomal-dominant
neurodegenerative disorder characterized by ataxia,
chorea, and dementia (Escames et al., 2010; Wang et al.,
2012). It is well known to be caused by an alteration in a
nuclear gene encoding huntingtin, a protein of unknown
function but associated with inappropriate apoptosis.
Mutant huntingtin protein first kills selectively vulnerable
medium spiny neurons in the striatum and thereafter
the cortical neurons (Wang et al., 2012). Additionally,
multiple mtDNA depletions have also been found in HD
patients, although their significance is unclear (Escames
et al., 2010). Current evidence from genetic models
supports mitochondrial dysfunction as a major cause of
the disease, including deficiencies in the activities of C-II,
C-III, and C-IV and calcium dyshomeostasis, impaired
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ATP production, and anomalous mitochondrial dynamics
(Escames et al., 2010; Srinivasan et al., 2010).
Amyotrophic lateral sclerosis (ALS) is a
neurodegenerative disease characterized by a progressive
and selective loss of motor neurons, resulting in progressive
paralysis and death. Although the exact pathophysiological
mechanisms are not fully understood, the occurrence of
apoptosis-related mitochondrial dysfunction in the spinal
cord-associated disease progression has been observed
(Zhang et al., 2013). On the other hand, in patients with the
familial form of ALS (5%–10%) mutations have been found
in the SOD1 gene that encodes the Cu, Zn-superoxide
dismutase 1; thus, mutant forms of this mitochondrial
antioxidant enzyme may damage mitochondria by some
misunderstood mechanism (Escames et al., 2010).
Since the role of mitochondria in neural cell
proliferation and/or differentiation seems to be essential,
melatonin’s effects in such cases might be related to its
close relation with mitochondrial function (Escames et al.,
2010). Therefore, the strategy in neurodegenerative diseases
may be the use of pharmacological agents with antioxidant
and free radical scavenging properties, leading to this goal
attained by endogenous melatonin (Patki et al., 2011). Data
obtained in animal models of different neural disorders
point out the ability of melatonin supplementation to limit
disfiguration of mtDNA (Reiter et al., 2008); restore GSH
levels; promote GPx and GRd activities (Phillipson, 2014);
prevent loss in mitochondrial C-I activity, mitochondrial
respiration, and ATP production (Dabbeni-Sala et al.,
2001; Morley et al., 2012); inhibit ΔΨm loss and release of
proapoptotic factors (Wang et al., 2012; Zhang et al., 2013);
and increase the numerical density and surface volume
of mitochondria (Morley et al., 2012). Furthermore,
melatonin supplementation could counteract cellular
vulnerability to proapoptotic challenge due to altered
melatonin receptors MT1 and MT2 observed in AD,
PD, HD, and ALS, increasing resistance to cellular stress
(Wang et al., 2012; Zhang et al., 2013). Other aspects such
as melatonin treatment that could also directly alter the
expression of the huntingtin gene, affecting disease onset,
progression, and survival of HD, must not be excluded
(Wang et al., 2012).
3.3. Cancer
Today in vitro evidence clearly shows that cancer cells
exhibit altered metabolic regulation and mitochondrial
morphology and physiology compared with normal cells
(Sheu et al., 2006). For instance, a study conducted in
rat prolactinoma cells showed elevated activities of C-I,
C-III, and C-IV along with higher production of ATP, an
important requirement for dividing cells. However, as the
authors noted, it cannot be forgotten that it is possible that
the ETC complexes display different degrees of increasing
activities in different tumor cells lines (Wang et al., 2013).

In this sense, the question of how cancer cells modulate
oxygen consumption by OXPHOS during the different
stages of tumorigenesis is still being discussed (Chen et al.,
2009).
As was previously emphasized, melatonin shows
proapoptotic effects on tumor cell lines compared to
normal cells (Bejarano et al., 2011a; Uguz et al., 2012).
In this sense, melatonin seems to be able to block ETC
complexes and decrease ATP production (Wang et al.,
2013), as well as activate the intrinsic apoptotic pathway
(Bejarano et al., 2009). Furthermore, antioxidant and
scavenger capacities of melatonin may also intervene
(Espino et al., 2010; Luchetti et al., 2010). As many studies
suggest, low melatonin levels observed during aging could
be linked to cancer progression (Wang et al., 2013).
3.4. Gastrointestinal and metabolic diseases
Compared to the pineal gland, the gastrointestinal tract
contains several hundred times more melatonin, where it is
believed to act as a synchronizer of the digestive processes,
a regulator of liver metabolism, and a protector from the
oxidant effects of biliary salts (Freitas et al., 2006).
Regarding chronic diabetes mellitus, enhanced
oxidative stress and declines in antioxidant capacity are
considered to play important roles in the pathogenesis of
this disease. At the mitochondrial level, ROS formation,
excessive oxidative damage, and reduced organular
biogenesis contribute to mitochondrial disruption and,
subsequently, to insulin resistance and associated diabetic
complications (Zavodnik et al., 2011). According to
Zavodnik et al. (2011), long-term melatonin administration
to diabetic rats reverts the oxygen consumption rate V3
and prevents the mitochondrial glutathione-S-transferase
inhibition in liver cells.
On the other hand, in metabolic diseases, such as
obesity, it has been observed that inflammatory cytokines
stimulate the generation of mitochondrial ROS and
induce oxidative/nitrosative stress that causes defective
aggregation of respiratory chain complexes; alteration in
organular bioenergetic has been also related to misshaped
mitochondria in renal proximal tubules of obese mice. In
this case, mitochondria were roundish when compared to
the elongated shape of mitochondria in control conditions,
as a consequence of renal oxidative stress. Melatonin
oral treatment modified mitochondrial morphology and
distribution in proximal tubules and greatly reduced
specific markers of the intrinsic apoptotic pathway
(Stacchiotti et al., 2014).
Regarding acute pancreatitis, the protective effect
of antioxidant supplementation in both oxidative and
inflammatory processes implied in this gastrointestinal
disease has been demonstrated. Thus, melatonin and
resveratrol are shown as chemopreventive agents against
oxidative phenomena such as lipid peroxidation and protein

827

CARRASCO et al. / Turk J Biol

oxidation, increasing antioxidant defenses (Carrasco et
al., 2013, 2014b) and regulating Ca2+ homeostasis at the
pancreatic level (Carrasco et al., 2014a).
3.5. Ischemia/reperfusion challenge in organ
transplantation and cerebrovascular accidents
Induced injury by cold ischemia/reperfusion (I/R) plays
a critical role in the occurrence of primary nonfunction
and delayed graft function, being limiting factors in
different organ transplantations such as heart and liver
(Freitas et al., 2006). Similarly, most cerebral ischemia
induced by various factors can be transiently reversed,
although reperfusion produces further neuron damage
(Han et al., 2006). After I/R, the oxidative stress, derived
from impairment of ETC function (C-I and C-III) among
other sources, is worsened by the concomitant depletion of
endogenous antioxidants. Mitochondrial ROS generation
occurs in part during ischemia and more abundantly
during early reperfusion. The decrease in ETC activity has
been ascribed to ROS-induced CL oxidation (Freitas et al.,
2006; Petrosillo et al., 2006). Moreover, in cardiomyocytes
and neurons it has also been observed that at reperfusion
the inﬂux of Ca2+ into the mitochondria combined with an
oxidative environment and higher pH causes the opening
of mPTP channels and therefore triggers the pathway of
cell death described above (Andrabi et al., 2004; Petrosillo
et al., 2009; Srinivasan et al., 2010).
For this reason, the use of melatonin could be a good
therapeutic option in I/R. Some experiments showed
that reperfusion with a melatonin-containing medium
significantly improved the restoration of liver function after
cold storage (Freitas et al., 2006). Furthermore, melatonin
reperfusion of ischemic hearts significantly lowered the
degree of mitochondrial lipid peroxidation, prevented the
loss in ETC function and the increase of H2O2 production
(Petrosillo et al., 2006), inhibited the formation of mPTP
and related events, and preserved the content and integrity
of CL molecules, suggesting a possible link between these
processes (Petrosillo et al., 2009; Paradies et al., 2010).
Focusing on the apoptotic pathway, it has been observed
that the indole inhibits cytochrome C release and caspase
1 and 3 activation, thus preventing DNA fragmentation
(Andrabi et al., 2004; Han et al., 2006; Wang et al., 2009). In
other words, scientific evidence indicates that melatonin’s
effect during I/R is not only due to its direct/indirect
antioxidant properties, but also due to its influence over
mitochondrial homeostasis and dynamics (Srinivasan
et al., 2010; Huang et al., 2013). Thus, in the case of a
stroke, it must be considered that elderly individuals may
be increasingly vulnerable to the damaging effects of this
accident because they lack appropriate protective levels of
endogenous melatonin (Andrabi et al., 2004).
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3.6. Sepsis and septic shock
Sepsis is the major cause of death in critical care units
worldwide and is characterized by systemic dysregulated
inflammatory response and oxidative stress, which can
culminate in organ failure and death (Lowes et al., 2011).
At the cellular level, data show mitochondrial dysfunction
with subsequent reduced C-I, C- II, and C-IV activities and
decreased ATP production, CL peroxidation, dissociation
of cytochrome C, and more ROS generation. These events
lead to an increased inflammatory response, resulting
in a self-sustaining and amplifying cycle. In fact, it is
well known that mitochondrial ROS drive inﬂammatory
cytokine responses such as IL-1b and IL-6 via both
inﬂammasome-dependent and -independent mechanisms
acting together with NFκβ. Septic experimental models
show that melatonin treatment restores mitochondrial
respiration and reduces both oxidative stress and IL-6
levels (Lowes et al., 2013).
On the other hand, septic shock is a lethal condition
caused by a complex chain of pathogen-induced events.
It has been associated with the production and release of
numerous proinﬂammatory mediators as well as massive
cellular apoptosis; as a result, a decrease in mitochondrial
respiration and in GSH levels as well as an overproduction
of ROS and NO is observed. Thus, it is suspected that
melatonin might exert a protective effect in mitochondrial
failure via regulation of mtiNOS activity, among other
mechanisms (Srinivasan et al., 2010).
3.7. Other diseases
UV-induced ROS generation is tightly connected with
skin photodamage. Melatonin shows protective effects
in photobiological disturbances not only for its strong
antioxidative properties, but also for its antiapoptotic
properties observed in keratinocytes and retinal pigment
epithelium cell cultures. The indole has been shown to
inhibit caspase 3 and 9 activation and to reduce dissipation
of mitochondrial transmembrane potential (Kleszczyński
et al., 2011; Argun et al., 2014).
Regarding alcoholism, ROS and other free radicals
generated during ethanol metabolism cause oxidative
stress and lipid peroxidation in the liver, brain, heart,
skeletal muscles, and exocrine pancreas. Mitochondria are
major targets of this oxidative damage, and in particular
some of their components such as proteins, CL, and
mtDNA. Scientific evidence shows that alcoholic binging
causes extensive mtDNA degradation and mtDNA
depletion in mouse heart, skeletal muscles, and brain,
followed by increased mtDNA replication and increased
mtDNA levels. Antioxidants such as melatonin exert
protective effects against ethanol-mediated hepatic
mtDNA depletion, likely due to its ability to incorporate
into mitochondrial membranes and bind to C-I (Mansouri
et al., 2001).
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In Barth syndrome, a genetic cardiomyopathy in
children, peroxidation of CL appears to be responsible, at
least in part, for the loss of the activity of ETC complexes
(C-I, C-III, and C-IV), mitochondrial dysfunction, and
subsequent heart injury (Paradies et al., 2010).
Finally, sudden infant death syndrome (SIDS), one of
the most mysterious disorders in medicine, could have
a mitochondrial origin. It has been hypothesized that
some infections, both viral and bacterial, can produce
profound alterations in the mitochondrial function of the
diaphragm, precipitating a significant reduction in the
ventilatory capacity of this muscle. Newborns and infants
born prematurely are especially prone to oxidative stress
and have reduced antioxidant defense mechanisms. Since
young infants exhibit transient melatonin deficiency for
the first 2–4 months of life and pineal dysfunction and
impaired melatonin metabolism have been associated with

SIDS, the role of the tryptophan–serotonin–melatonin
pathway in the etiology of SIDS should be investigated in
the future (Siren et al., 2011).
4. Conclusion
Mitochondrial dyshomeostasis and related events have
begun to reveal themselves as possible etiologies of several
diseases of unknown origin. In the next years, conscientious
investigation about this topic should be undertaken by
scientists of different research areas to achieve a better
understanding of the molecular mechanisms implied,
which will ultimately allow the development and clinical
application of efficacious treatments.
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